Investing

Merck in late-stage talks to acquire Prometheus Biosciences -WSJ

Published

2 years ago

on

© Reuters. FILE PHOTO: Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly

(Reuters) – Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.

Read the full article here

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version